|
|||||
|
|
Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane |
|
| Authors: | Nicoletta Bertorello Roberto Luksch Gianni Bisogno Riccardo Haupt Paolo Spallarossa Rosita Cenna Franca Fagioli |
| Affiliation: | 1. Paediatric Oncology Division, Regina Margherita Children's Hospital, AOU Città della Salute e della Scienza, Turin, Italy;2. Paediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;3. Hematology and Oncology Division, Department of Women's and Children's Health, University of Padova, Padua, Italy;4. Epidemiology and Biostatistics Unit and DOPO clinic, IRCCS Istituto Giannina Gaslini, Genoa, Italy;5. Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy;6. Paediatric Oncology Division, Regina Margherita Children's Hospital, AOU Città della Salute e della Scienza, Turin, Italy University of Turin, Turin, Italy |
| Abstract: | Cardiovascular disease is the leading cause of non-malignant morbidity and mortality in childhood cancer survivors (CCSs). Anthracyclines are included in many treatment regimens for paediatric cancer, but unfortunately, these compounds are cardiotoxic. One in 10 CCSs who has received an anthracycline will develop a symptomatic cardiac event over time. Given the crucial need to mitigate anthracycline-related cardiotoxicity (ARC), the authors critically examined published data to identify effective cardioprotective strategies. Based on their expert analysis of contemporary literature data, it was concluded that consideration should be given for routine use of dexrazoxane in children with cancer who are at risk of ARC. |
| Keywords: | anthracyclines cardioprotection cardiotoxicity childhood cancer survivors dexrazoxane doxorubicin |